Here's a bit of good news for anyone trying to get their hands on Novo Nordisk's (NVO) popular weight-loss drug Wegovy in Europe: you might not need to worry about it spoiling on the way home from the pharmacy anymore.
The European Medicines Agency said on Thursday that it's okay for the final leg of Wegovy's journey—from the pharmacy to your doorstep—to happen at regular room temperature. As long as it's not hotter than 30°C (that's about 86°F for those of us who think in Fahrenheit) and the trip takes no more than 48 hours, the injection can travel without a fridge. That's a pretty big deal because until now, Wegovy had to stay chilled from the factory all the way to the patient, a process known as cold-chain logistics.
Think of it like this: getting a perishable item delivered used to be like ordering a specific ice cream that had to come in a special cooler. Now, it's more like getting groceries that can sit on your porch for a couple of days in decent weather. This shift makes Wegovy the first GLP-1 therapy in Europe with this kind of delivery flexibility.
So, why does this matter? For starters, it simplifies life for pharmacies and online partners. Less reliance on refrigeration means lower transportation costs, less bulky packaging, and generally a smoother supply chain. It's a logistical win that could trickle down to make the drug easier and potentially cheaper to distribute.
This update is particularly timely as more healthcare moves online. Greater delivery flexibility could make it more feasible for eHealth channels and online pharmacies to offer Wegovy through home delivery services across Europe. It's a nod to the growing trend of direct-to-patient models.
A quick but important note: this change only applies to the Wegovy injection. Patient guidance on storage after you get it hasn't changed—once you start using a pen, you can keep it at room temperature (below 30°C) for up to 28 days or just pop it back in the fridge. Also, this is separate from the Wegovy pill, which doesn't need refrigeration at all. The pill is already approved in the U.S. and is waiting for a regulatory decision in the EU later this year.
This delivery update isn't happening in a vacuum. Just last month, Novo Nordisk rolled out a multi-month subscription program for Wegovy, aiming to make the cost more predictable for patients who pay out of pocket and to help with long-term adherence. The program, available since March 31, 2026, lets eligible patients get the FDA-approved treatment through select telehealth providers for a fixed monthly fee.
On the market front, Novo Nordisk shares were down 0.61% at $37.38 at the time of publication on Thursday. The stock is hovering near its 52-week low of $35.11, according to market data.
